VKTX Latest Press Releases

-- October 21, 2026 --

Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026 PRNewswire 4:06 PM

-- October 14, 2026 --

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity PRNewswire 7:05 AM

-- October 6, 2026 --

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity PRNewswire 7:07 AM

-- September 28, 2026 --

Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes PRNewswire 4:30 PM

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm PRNewswire 11:12 AM

-- September 24, 2026 --

Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes PRNewswire 7:05 AM

-- September 23, 2026 --

Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes PRNewswire 4:34 PM

-- September 22, 2026 --

Today's Best Stocks to Watch: Weight-Loss Wars, Biotech and Critical Minerals Globe Newswire 10:31 AM

Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens PRNewswire 7:05 AM

-- September 2, 2026 --

Viking Therapeutics to Participate at Upcoming Investor Conferences PRNewswire 4:06 PM

-- July 29, 2026 --

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update PRNewswire 4:05 PM

-- July 23, 2026 --

Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors PRNewswire 7:39 AM

-- July 22, 2026 --

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026 PRNewswire 4:05 PM

-- July 21, 2026 --

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm PRNewswire 4:41 PM

-- July 16, 2026 --

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm Globe Newswire 9:31 PM

-- June 24, 2026 --

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults PRNewswire 7:05 AM

-- June 11, 2026 --

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer PRNewswire 7:05 AM

Market Data Delayed 15 Minutes